In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants

Journal of Virology

Volumn 80, Issue 23, 2006, Pages 11651-11657

  Zhao, Xiaodong ^a   Liu, Enmei ^a   Chen, Fu Ping ^b   Sullender, Wayne M ^b,c,d  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MONOCLONAL ANTIBODY; PALIVIZUMAB;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; COTTON RAT; DRUG DESIGN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIROGENESIS; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; MUTATION; RESPIRATORY SYNCYTIAL VIRUSES; RNA, VIRAL; SIGMODONTINAE; VIRUS REPLICATION;

MURINAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; SIGMODON;

EID: 33751334650     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01387-06     Document Type: Article

References (48)

1. Baranowski, E., N. Sevilla, N. Verdaguer, C. M. Ruiz-Jarabo, E. Beck, and J E. Domingo. 1998. Multiple virulence determinants of foot-and-mouth disease virus in cell culture. J. Virol. 72:6362-6372.
2. Beeler, J. A., and K. van Wyke Coelingh. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63:2941-2950.
3. Carman, W., A. Zanett, P. Karayiannis, J. Waters, G. Manzillo, E. Tanzi, A. Zuckerman, and H. Thomas. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329.
4. Carsillo, T., X. Zhang, D. Vasconcelos, S. Niewiesk, and M. Oglesbee. 2006. A single codon in the nucleocapsid protein C terminus contributes to in vitro and in vivo fitness of Edmonston measles virus. J. Virol. 80:2904-2912.
5. Collins, P., R. Chanock, and B. Murphy. 2001. Respiratory syncytial virus, p. 1443-1485. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed., vol. 1. Lippincot Williams & Wilkins, Philadelphia, Pa.
6. DeVincenzo, J. P., C. B. Hall, D. W. Kimberlin, P. J. Sanchez, W. J. Rodriguez, B. A. Jantausch, L. Corey, J. S. Kahn, J. A. Englund, J. A. Suzich, F. J. Palmer-Hill, L. Branco, S. Johnson, N. K. Patel, and F. M. Piazza. 2004. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J. Infect. Dis. 190:975-978.
7. Domingo, E., and J. Holland. 1994. Mutation rates and rapid evolution of RNA viruses, p. 161-184. In S. Morse (ed.), The evolutionary biology of viruses. Raven Press, New York, N.Y.
8. Dowell, S., L. Anderson, H. Gary, D. Erdman, J. Plouffe, T. File, B. Marston, and R. Breiman. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174:456-462.
9. Duarte, E., D. Clarke, A. Moya, E. Domingo, and J. Holland. 1992. Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proc. Natl. Acad. Sci. USA. 89:6015-6019.
10. Duarte, E. A., I. S. Novella, S. Ledesma, D. K. Clarke, A. Moya, S. F. Elena, E. Domingo, and J. J. Holland. 1994. Subclonal components of consensus fitness in an RNA virus clone. J. Virol. 68:4295-4301.
11. Ellis, G. M., M. Mahalanabis, I. A. Beck, G. Pepper, A. Wright, S. Hamilton, S. Holte, W. E. Naugler, D. M. Pawluk, C.-C. Li, and L. M. Frenkel. 2004. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J. Clin. Microbiol. 42:3670-3674.
12. El Saleeby, C., J. Suzich, M. Conley, and J. DeVincenzo. 2004. Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. Clin. Infect. Dis. 39:e17-e20. [Online.]
13. Englund, J. A., C. J. Sullivan, M. C. Jordan, L. P. Dehner, G. M. Vercellotti, and H. H. Balfour, Jr. 1988. Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 109:203-208.
14. Escarmís, C., M. Dávila, N. Charpentier, A. Bracho, A. Moya, and E. Domingo. 1996. Genetic lesions associated with Muller's ratchet in an RNA virus. J. Mol. Biol. 264:255-267.
15. Falsey, A. 1998. Respiratory syncytial virus infection in older persons. Vaccine 16:1775-1778.
16. Garcia-Barreno, B., A. Portela, T. Delgado, J. A. Lopez, and J. A. Melero. 1990. Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J. 9:4181-4187.
17. Groothuis, J. R., K. M. Gutierrez, and B. A. Lauer. 1988. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 82:199-203.
18. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
19. Hamre, D., C. Loosli, and P. Gerber. 1958. Antigenic variants of influenza A virus (PR8 strain). III. Serological relationships of a line of variants derived in sequence in mice given homologous vaccine. J. Exp. Med. 107:829-844.
20. Henderson, F., A. Collier, W. Clyde, and F. Denny. 1979. Respiratory syncytial virus infections, reinfections and immunity. N. Engl. J. Med. 300:530-534.
21. Holland, J. J., J. C. De La Torre, D. K. Clarke, and E. Duarte. 1991. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J. Virol. 65:2960-2967.
22. Hyslop, N. G., and R. Fagg. 1965. Isolation of variants during passage of a strain of foot-and-mouth disease virus in partly immunized cattle. J. Hyg. 63:357-368.
23. IMPACT-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537.
24. Johnson, R. A., G. A. Prince, S. C. Suffin, R. L. Horswood, and R. M. Chanock. 1982. Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. Infect. Immun. 37:369-373.
25. Lahser, F. C., J. Wright-Minogue, A. Skelton, and B. A. Malcolm. 2003. Quantitative estimation of viral fitness using Pyrosequencing. BioTechniques 34:26-28.
26. Lopez, J., C. Penas, B. Garcia-Barreno, J. Melero, and A. Portela. 1990. Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus. J. Virol. Methods 64:927-930.
27. López-Bueno, A., M. G. Mateu, and J. M. Almedral. 2003. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J. Virol. 77:2701-2708.
28. MacDonald, N. E., C. B. Hall, S. C. Suffin, C. Alexson, P. J. Harris, and J. A. Manning. 1982. Respiratory syncytial viral infection in infants with congenital heart disease. N. Engl. J. Med. 307:397-400.
29. Martinez-Picado, J., J. G. Prado, E. E. Fry, K. Pfafferott, A. Leslie, S. Chetty, C. Thobakgale, I. Honeyborne, H. Crawford, P. Matthews, T. Pillay, C. Rousseau, J. I. Mullins, C. Brander, B. D. Walker, D. I. Stuart, P. Kiepiela, and P. Goulder. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80:3617-3623.
30. Nijhuis, M., C. A. B. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. USA 95:14441-14446.
31. Novella, I. S., L. A. Ball, and G. W. Wertz. 2004. Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J. Virol. 78:9837-9841.
32. Novella, I. S., D. D. Reissig, and C. O. Wilke. 2004. Density-dependent selection in vesicular stomatitis virus. J. Virol. 78:5799-5804.
33. Nurpeisov, V., S. J. Hurwitz, and P. L. Sharma. 2003. Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase. J. Clin. Microbiol. 41:3306-3311.
34. Peret, T., C. Hall, G. Hammond, P. Piedra, G. Storch, W. Sullender, C. Tsou, and L. Anderson. 2000. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J. Infect. Dis. 181:1891-1896.
35. Prado, J. G., S. Franco, T. Matamoros, L. Ruiz, B. Clotet, L. Menéndez-Arias, M. Á. Martínez, and J. Martinez-Picado. 2004. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 326:103-112.
36. PREVENT Study Group. 1997. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93-99.
37. Protzer-Knolle, U., U. Naumann, R. Bartenschlager, T. Berg, U. Hopf, K. Hermann, M. zum-Büschenfelde, P. Neuhaus, and G. Gerken. 1998. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263.
38. Sevilla, N., C. Ruiz-Jarabo, G. Gomez-Mariano, E. Baranowski, and E. Domingo. 1998. An RNA virus can adapt to the multiplicity of infection. J. Gen. Virol. 79:2971-2980.
39. Shann, F., and M. C. Steinhoff. 1999. Vaccines for children in rich and poor countries. Lancet 354:7-11.
40. Shay, D., R. Holman, L. Liu, J. Stout, and L. Anderson. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446.
41. Sullender, W., and K. Edwards. 1999. Mutations of respiratory syncytial virus attachment glycoprotein G associated with resistance to neutralization by primate polyclonal antibodies. Virology 264:230-236.
42. Weaver, S. C., A. C. Brault, W. Kang, and J. J. Holland. 1999. Genetic and fitness changes accompanying adaptation of an arbovirus to vertebrate and invertebrate cells. J. Virol. 73:4316-4326.
43. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
44. Whitehead, S., C. Firestone, P. Collins, and B. Murphy. 1998. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247:232-239.
45. Wolf, D. G., I. L. Smith, D. J. Lee, W. R. Freeman, M. Flores-Aguilar, and S. A. Spector. 1995. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Investig. 95:257-263.
46. Zhao, X., F. P. Chen, A. G. Megaw, and W. M. Sullender. 2004. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J. Infect. Dis. 190:1941-1946.
47. Zhao, X., F. P. Chen, and W. M. Sullender. 2004. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318:608-612.
48. Zhao, X., and W. M. Sullender. 2005. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J. Virol. 79:3962-3968.